FDA Clears New PET/CT Scanner from Siemens Healthineers

News
Article

The Biograph Vision.X positron emission tomography/computed tomography (PET/CT) reportedly offers an industry-leading time of flight (TOF) and detector technology that facilitates the diagnosis of smaller lesions.

Offering an array of technological advantages with positron emission tomography/computed tomography (PET/CT), the Biograph Vision.X™ system has garnered 510(k) clearance from the Food and Drug Administration (FDA).

The Biograph Vision.X features a time of flight (TOF) of 178 picoseconds and Optiso Ultra Dynamic Range (UDR) detector technology, according to Siemens Healthineers, the manufacturer of the device. Utilizing 3.2 x 3.2 mm lutetium oxyorthosilicate (LSO) crystal elements that provide enhanced spatial resolution in comparison to larger crystals, the company noted the UDR technology enables 48 mm3 volumetric resolution and temporal resolution of 178 ps.

“The Biograph Vision.X’s record-shattering, ultrafast time of flight delivers an image resolution that allows even the smallest lesions to rise above the noise,” said James Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “This extremely high level of resolution can help physicians detect small lesions and provide patients with a precise diagnosis.”

In order to optimize radiology workflow, Siemens Healthineers said the system’s built-in AIDAN intelligent imaging platform has a foundation of over 700 patents in machine learning and deep learning applications. The company added that the optional FlowMotion™ AI feature for the Biograph Vision.X device enables clinicians to personalize image acquisition with one click via a combination of anatomical AI and continuous bed motion.

Recent Videos
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.